Market Research Logo

Hypoglycemia - Pipeline Review, H2 2015

Hypoglycemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hypoglycemia - Pipeline Review, H2 2015’, provides an overview of the Hypoglycemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypoglycemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hypoglycemia Overview
Therapeutics Development
Pipeline Products for Hypoglycemia - Overview
Pipeline Products for Hypoglycemia - Comparative Analysis
Hypoglycemia - Therapeutics under Development by Companies
Hypoglycemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hypoglycemia - Products under Development by Companies
Hypoglycemia - Companies Involved in Therapeutics Development
Biodel Inc.
Eli Lilly and Company
Heptares Therapeutics Limited
Novartis AG
SkyePharma Plc
USV Limited
XERIS Pharmaceuticals, Inc.
XOMA Corporation
Zealand Pharma A/S
Hypoglycemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Biologic for Hypoglycemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbutaline sulphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA-358 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZP-4207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypoglycemia - Recent Pipeline Updates
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Jun 26, 2015: Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia
May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial
Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
Nov 17, 2014: Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development
Jun 17, 2014: Zealand presented new data on ZP-GA-1 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions
Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypoglycemia, H2 2015
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Hypoglycemia - Pipeline by Biodel Inc., H2 2015
Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2015
Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2015
Hypoglycemia - Pipeline by Novartis AG, H2 2015
Hypoglycemia - Pipeline by SkyePharma Plc, H2 2015
Hypoglycemia - Pipeline by USV Limited, H2 2015
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2015
Hypoglycemia - Pipeline by XOMA Corporation, H2 2015
Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hypoglycemia Therapeutics - Recent Pipeline Updates, H2 2015
Hypoglycemia - Dormant Projects, H2 2015
Hypoglycemia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Hypoglycemia, H2 2015
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report